Wedbush Reaffirms Ovid Therapeutics At Outperform With Price Target Of $7

AI Briefing

• – Wedbush reaffirms Ovid Therapeutics at Outperform with price target of $7.
• – Analyst Laura Chico notes KCC2 R&D Event on April 14, 2026, as key catalyst.
• – Event is expected to drive stock's growth prospects.